We last looked at Pfizer (PFE) back on March 8 and wrote that "PFE may continue to hold around $34 and that's okay but the quantitative downgrade to hold and a Point and Figure target of $30 tells us to be careful as we could see a retest of the June low in the weeks ahead. It may not happen but luck favors the prepared."
More from Investing
The elevator maker's charts are pushing the right buttons.
Why we ever allowed Chinese businesses to raise capital, our capital, on our shores, is beyond me.
Conditions for 'sell the news' action is good, but is it too obvious to actually work?
The reopening stocks did well on Monday, but the underlying statistics in the market are shaky.
The Fed hopes its efforts will lead to sustainable GDP growth, but if inflation starts to run away too quickly, then Powell and company's hands could be tied.